MA33445B1 - Dérivés 17-hydroxy-17-pentafluoréthyl-estra-4,9(10)-diène-11-arylés, leur procédé de production et leur utilisation pour le traitement de maladies - Google Patents

Dérivés 17-hydroxy-17-pentafluoréthyl-estra-4,9(10)-diène-11-arylés, leur procédé de production et leur utilisation pour le traitement de maladies

Info

Publication number
MA33445B1
MA33445B1 MA34552A MA34552A MA33445B1 MA 33445 B1 MA33445 B1 MA 33445B1 MA 34552 A MA34552 A MA 34552A MA 34552 A MA34552 A MA 34552A MA 33445 B1 MA33445 B1 MA 33445B1
Authority
MA
Morocco
Prior art keywords
diseases
treatment
production
diene
hydroxy
Prior art date
Application number
MA34552A
Other languages
Arabic (ar)
English (en)
Inventor
Wolfgang Schwede
Ulrich Klar
Carsten Möller
Andrea Rotgeri
Wilhelm Bone
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43383964&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33445(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MA33445B1 publication Critical patent/MA33445B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des dérivés 17-hydroxy-17-pentafluoréthyl-estra-4,9(10)-diène-11-arylés de formule (I) ayant un effet antagoniste sur la progestérone et leur procédé de production, leur utilisation pour le traitement et/ou la prophylaxie de maladies ainsi que leur utilisation pour la production de médicaments destinés au traitement et/ou à la prophylaxie de maladies, en particulier des fibromes utérins (myomes, léiomyomes utérins), de l'endométriose, des règles importantes, des méningiomes, des cancers du sein hormono-dépendants et des troubles associés à la ménopause, ou au contrôle de la fertilité et à la contraception d'urgence.
MA34552A 2009-07-20 2010-07-07 Dérivés 17-hydroxy-17-pentafluoréthyl-estra-4,9(10)-diène-11-arylés, leur procédé de production et leur utilisation pour le traitement de maladies MA33445B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102009034362A DE102009034362A1 (de) 2009-07-20 2009-07-20 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
PCT/EP2010/004149 WO2011009531A2 (fr) 2009-07-20 2010-07-07 Dérivés 17-hydroxy-17-pentafluoréthyl-estra-4,9(10)-diène-11-arylés, leur procédé de production et leur utilisation pour le traitement de maladies

Publications (1)

Publication Number Publication Date
MA33445B1 true MA33445B1 (fr) 2012-07-03

Family

ID=43383964

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34552A MA33445B1 (fr) 2009-07-20 2010-07-07 Dérivés 17-hydroxy-17-pentafluoréthyl-estra-4,9(10)-diène-11-arylés, leur procédé de production et leur utilisation pour le traitement de maladies

Country Status (47)

Country Link
US (4) US20120149670A1 (fr)
EP (4) EP2432798B1 (fr)
JP (3) JP5795312B2 (fr)
KR (2) KR101687853B1 (fr)
CN (1) CN102482317B (fr)
AR (1) AR077491A1 (fr)
AU (1) AU2010275849B2 (fr)
BR (1) BR112012001344B8 (fr)
CA (1) CA2768407C (fr)
CL (1) CL2012000166A1 (fr)
CO (1) CO6491067A2 (fr)
CR (2) CR20170091A (fr)
CU (1) CU20120012A7 (fr)
CY (3) CY1114260T1 (fr)
DE (1) DE102009034362A1 (fr)
DK (3) DK2623510T3 (fr)
DO (2) DOP2012000015A (fr)
EA (2) EA021946B1 (fr)
EC (2) ECSP12011616A (fr)
ES (3) ES2416461T3 (fr)
GT (1) GT201200012A (fr)
HN (1) HN2012000137A (fr)
HR (3) HRP20130558T1 (fr)
HU (2) HUE037339T2 (fr)
IL (1) IL216967B (fr)
IN (1) IN2012DN00598A (fr)
JO (2) JO3009B1 (fr)
LT (2) LT3252069T (fr)
MA (1) MA33445B1 (fr)
ME (2) ME03400B (fr)
MX (2) MX2012000930A (fr)
MY (1) MY179447A (fr)
NO (1) NO2623510T3 (fr)
NZ (2) NZ623417A (fr)
PE (2) PE20170084A1 (fr)
PL (3) PL2432798T3 (fr)
PT (3) PT3252069T (fr)
RS (1) RS52811B (fr)
SG (3) SG10201811830PA (fr)
SI (3) SI2432798T1 (fr)
TN (1) TN2012000028A1 (fr)
TR (1) TR201908600T4 (fr)
TW (1) TWI505830B (fr)
UA (1) UA106502C2 (fr)
UY (1) UY32791A (fr)
WO (1) WO2011009531A2 (fr)
ZA (1) ZA201201222B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034362A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102011088270A1 (de) 2011-12-12 2013-06-13 Bayer Intellectual Property Gmbh (11ß ,17ß)-17-hydroxy-11-[4-(methylsulfonyl)phenyl]-17-(pentafluorethyl)estra-4,9-dien-3-on zur Behandlung von Morbus Charcot Marie Toot
EP2983671B1 (fr) * 2013-04-11 2018-10-24 Bayer Pharma Aktiengesellschaft Forme posologique de l'antagoniste du récepteur de la progestérone
US9096641B2 (en) 2013-06-05 2015-08-04 Evestra, Inc. Imidazolyl progesterone antagonists
KR20180004814A (ko) * 2015-05-18 2018-01-12 바이엘 파마 악티엔게젤샤프트 선택적 프로게스테론 수용체 조절제 (sprm) 요법
EP3214092A1 (fr) 2016-03-04 2017-09-06 Bayer Pharma Aktiengesellschaft Promédicaments du modulateur du récepteur de progesterone (sprm) (11.bêta.,17.bêta.)-17-hydroxy-11-[4-(méthylsulphonyle)phenyle]-17-(pentafluoroéthyl)estra-4,9-dièn-3-one
EP3384913A1 (fr) * 2017-04-03 2018-10-10 Bayer Pharma Aktiengesellschaft Modulateurs sélectifs du récepteur de la progestérone et niveau d' strogène stabilisé chez un patient
CN111225671A (zh) * 2017-10-26 2020-06-02 苏州科睿思制药有限公司 一种选择性孕酮受体调节剂的晶体及其制备方法
US12491227B2 (en) 2022-03-01 2025-12-09 Altin Biosciences Corporation Crila® and EGCG compositions for treatment of fibroids

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA8231B (en) 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
DE3347126A1 (de) * 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen 11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
FR2596395B1 (fr) * 1986-03-26 1989-05-26 Roussel Uclaf Nouveaux steroides comportant un cycle spirannique en position 17, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
US5272140A (en) 1987-01-23 1993-12-21 Akzo N.V. 11-aryl steroid derivatives
FR2620707B1 (fr) 1987-09-18 1989-12-08 Roussel Uclaf Nouveaux steroides comportant un cycle spirannique a 3, 4 ou 6 chainons en position 17, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
FR2644789B1 (fr) 1989-03-22 1995-02-03 Roussel Uclaf Nouveaux steroides 19-nor, 3-ceto comportant une chaine en 17 aminosubstituee, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les contenant
JP3202224B2 (ja) 1989-08-04 2001-08-27 シエーリング アクチエンゲゼルシヤフト １１β―アリール―ゴナ―４，９―ジエン―３―オン、その製造方法及びそれを含有する調剤学的調製剤
US5407928A (en) 1990-08-15 1995-04-18 Schering Aktiengesellschaft 11β-aryl-gona-4,9-dien-3-ones
CA2100514C (fr) * 1992-07-29 2005-03-29 Johannes A. M. Hamersma Steroides de type 17-spiromethylene
FR2718354B1 (fr) 1994-04-08 1996-05-03 Roussel Uclaf Application des composés antiglucocorticoïde pour la préparation de médicaments destinés à la prévention ou au traitement des manifestations liées au syndrome de sevrage des narcotiques et les compositions les renfermant.
DE4426601A1 (de) 1994-07-27 1996-02-01 Schering Ag Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri
EP1488794A3 (fr) 1994-11-22 2005-04-20 Balance Pharmaceuticals, Inc. Méthodes de contraception
PT900234E (pt) 1996-05-01 2000-12-29 Us Gov Health & Human Serv Derivados de progesterona substituidos em 21 que podem ser utilizados como novos agentes antiprogestativos
WO1998005679A2 (fr) 1996-08-05 1998-02-12 Duke University Antagonistes mixtes du recepteur progesterone et techniques de dosage associees
DE19635525A1 (de) 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
FR2757400B1 (fr) 1996-12-19 1999-12-17 Hoechst Marion Roussel Inc Application des composes antiglucocorticoides dans le traitement des psychoses ou des comportements addictifs
DE19706061A1 (de) 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
US20010016578A1 (en) 1997-06-18 2001-08-23 Balance Pharmaceuticals, Inc. Compositions and methods for contraception and for treatment of benign gynecological disorders
JPH11171774A (ja) 1997-12-05 1999-06-29 Kyowa Hakko Kogyo Co Ltd 血球増多剤
AR015500A1 (es) 1997-12-23 2001-05-02 Schering Ag 11 BETA-HALoGENO-ESTRATRIENOS SUSTITUIDOS EN 7 ALFA, PROCEDIMIENTO PARA ELABORAR PREPARADOS FARMACEUTICOS QUE CONTIENEN TALES 11 BETA-HALOGENO-ESTRATRIENOSSUSTITUIDOS EN 7 ALFA, ASI COMO SU UTILIZACION EN LA ELABORACION DE MEDICAMENTOS.
US6020328A (en) 1998-03-06 2000-02-01 Research Triangle Institute 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
WO1999053924A1 (fr) 1998-04-17 1999-10-28 Kyowa Hakko Kogyo Co., Ltd. Agent analgesique
US6172052B1 (en) * 1998-12-04 2001-01-09 Research Triangle Institute 17β-acyl-17α-propynyl-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US6476079B1 (en) 1999-12-23 2002-11-05 Leiras Oy Devices for the delivery of drugs having antiprogestinic properties
EP1157996A1 (fr) 2000-05-23 2001-11-28 JENAPHARM GmbH Nouveaux formes solides du mesoprogestin 11beta-(4E-(hxdroxyiminomethyl)-phenyl)-17alpha-methoxymethyl-17beta-methoxy-estra-4,9-dien-3-on
PT1325022E (pt) 2000-09-18 2006-12-29 Applied Research Systems Método para a preparação de 21-hidroxi-6, 19-oxido-progesterona (210h-60p)
DE10051609A1 (de) 2000-10-18 2002-05-02 Schering Ag Hemmung der Wachstumsfaktorabhängigkeit von Tumorzellen
DK1328276T3 (da) 2000-10-18 2006-04-03 Schering Ag Anvendelse af antiprogestiner til profylakse og behandling af hormonafhængige sygdomme
WO2002032429A2 (fr) 2000-10-18 2002-04-25 Schering Aktiengesellschaft Inhibition de la dependance des cellules tumorales par rapport au facteur de croissance
ATE367817T1 (de) * 2001-01-09 2007-08-15 Bayer Schering Pharma Ag Verwendung von antigestagene zur verschiebung der endometrialen reifung wahrend infertilitätbehandlung
US20020143000A1 (en) * 2001-01-09 2002-10-03 Christa Hegele-Hartung Use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment
DE10159217A1 (de) 2001-11-27 2003-06-05 Schering Ag 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate
DE10221034A1 (de) 2002-05-03 2003-11-20 Schering Ag 17alpha-Fluoralkyl-11ß-benzaldoxim-Steroide, Verfahren zu deren Herstellung, diese Steroide enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
WO2003093292A1 (fr) 2002-05-03 2003-11-13 Schering Ag Steroides constitues de 17$g(a)-fluoroalkyl-11$g(b)-benzaldoxime, leur procede de preparation, preparations pharmaceutiques contenant lesdits steroides ainsi que leur utilisation pour la production de medicaments
DE602005026290D1 (de) 2004-07-09 2011-03-24 Population Council Inc Zusammensetzungen mit verzögerter freisetzung mit progesteron-rezeptormodulatoren
WO2006101009A1 (fr) 2005-03-18 2006-09-28 Hirose Engineering Co., Ltd. Compose luminescent rouge a base de rouge du nil et element luminescent l’utilisant
US20070105828A1 (en) 2005-08-19 2007-05-10 Glenmark Pharmaceuticals Limited Novel polymorph form M of mifepristone and process for its preparation
EP1862468A1 (fr) 2006-06-02 2007-12-05 Bayer Schering Pharma Aktiengesellschaft 11beta-(4-Acetylphenyle)-20,20,21,21,21-pentafluor-17-hydroxy-19-nor-17alpha-pregna-4,9-dien-3-one crystalline
DE102006054535A1 (de) 2006-11-15 2008-05-21 Bayer Schering Pharma Aktiengesellschaft Progesteronrezeptorantagonisten
US20090075989A1 (en) * 2006-12-21 2009-03-19 Wolfgang Schwede Non-steroidal progesterone receptor modulators
WO2008105876A1 (fr) 2007-03-01 2008-09-04 Prs Mediterranean Ltd. Système de confinement cellulaire multicouche résistant aux uv
EP2123279A1 (fr) 2008-05-14 2009-11-25 Bayer Schering Pharma Aktiengesellschaft Administration séquentielle de 20,20,21,21,21-Ppentafluor-17-hydroxy-1 1bêta-[4-(hydroxyacétyl) phényl]-19-nor-17alpha-pregna-4,9-dien-3-on et un ou plusieurs gestagènes destinés au traitement de maladies gynécologiques
DE102009034362A1 (de) * 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten

Also Published As

Publication number Publication date
AR077491A1 (es) 2011-08-31
DOP2015000276A (es) 2018-04-15
CL2012000166A1 (es) 2012-08-31
CY1121926T1 (el) 2020-10-14
CR20120040A (es) 2012-03-12
JP2015178522A (ja) 2015-10-08
SI2623510T1 (sl) 2017-12-29
EP3272763A1 (fr) 2018-01-24
MX2012000930A (es) 2012-03-26
KR20120046182A (ko) 2012-05-09
KR101854059B1 (ko) 2018-05-02
SI2432798T1 (sl) 2013-08-30
TWI505830B (zh) 2015-11-01
RS52811B (sr) 2013-10-31
ES2416461T3 (es) 2013-08-01
SG10201404159VA (en) 2014-10-30
TR201908600T4 (tr) 2019-07-22
EP2623510B1 (fr) 2017-08-23
CA2768407A1 (fr) 2011-01-27
PT2432798E (pt) 2013-06-28
US10155004B2 (en) 2018-12-18
DK3252069T3 (da) 2019-06-24
GT201200012A (es) 2013-10-15
CU20120012A7 (es) 2012-07-31
HK1171456A1 (en) 2013-03-28
HUE043757T2 (hu) 2019-09-30
US20120094969A1 (en) 2012-04-19
CN102482317A (zh) 2012-05-30
DE102009034362A1 (de) 2011-01-27
CY1119661T1 (el) 2018-04-04
PT3252069T (pt) 2019-06-18
US20150342962A1 (en) 2015-12-03
NZ623417A (en) 2015-10-30
CU24080B1 (fr) 2015-03-30
PE20170084A1 (es) 2017-03-30
SI3252069T1 (sl) 2019-06-28
ME03400B (fr) 2020-01-20
BR112012001344B1 (pt) 2020-09-24
EA021946B1 (ru) 2015-10-30
AU2010275849A1 (en) 2012-02-02
CA2768407C (fr) 2017-10-24
JP6130087B1 (ja) 2017-05-17
IL216967A0 (en) 2012-02-29
IN2012DN00598A (fr) 2015-06-12
EP2623510A1 (fr) 2013-08-07
DK2432798T3 (da) 2013-07-01
BR112012001344A2 (pt) 2016-03-15
KR20160093110A (ko) 2016-08-05
EP2432798A2 (fr) 2012-03-28
DOP2012000015A (es) 2016-04-15
US20120149670A1 (en) 2012-06-14
JO3732B1 (ar) 2021-01-31
AU2010275849B2 (en) 2014-12-18
NZ597639A (en) 2014-04-30
CO6491067A2 (es) 2012-07-31
HUE037339T2 (hu) 2018-08-28
US8278469B2 (en) 2012-10-02
KR101687853B1 (ko) 2016-12-19
CY1114260T1 (el) 2016-08-31
ES2648292T3 (es) 2017-12-29
EP2432798B1 (fr) 2013-04-03
NO2623510T3 (fr) 2018-01-20
DK2623510T3 (en) 2017-12-04
EP3252069A1 (fr) 2017-12-06
LT3252069T (lt) 2019-06-10
JP5795312B2 (ja) 2015-10-14
SG177519A1 (en) 2012-02-28
CR20170091A (es) 2018-02-06
SG10201811830PA (en) 2019-02-27
UA106502C2 (uk) 2014-09-10
EA201301263A1 (ru) 2014-08-29
IL216967B (en) 2018-06-28
MY179447A (en) 2020-11-06
PL2623510T3 (pl) 2018-02-28
ECSP12011616A (es) 2012-02-29
EA201200121A1 (ru) 2012-07-30
EA025150B1 (ru) 2016-11-30
HRP20171805T1 (hr) 2017-12-29
HRP20130558T1 (hr) 2013-07-31
LT2623510T (lt) 2017-12-11
JP2017105813A (ja) 2017-06-15
HN2012000137A (es) 2015-05-04
TW201105331A (en) 2011-02-16
EP3252069B1 (fr) 2019-04-03
PT2623510T (pt) 2017-11-24
ES2730209T3 (es) 2019-11-08
MX338217B (es) 2016-04-07
ECSP18047708A (es) 2018-06-30
CN102482317B (zh) 2014-09-17
WO2011009531A2 (fr) 2011-01-27
JP2012533575A (ja) 2012-12-27
PL3252069T3 (pl) 2019-09-30
ME01534B (me) 2014-04-20
BR112012001344B8 (pt) 2021-05-25
PL2432798T3 (pl) 2013-08-30
US20170202857A1 (en) 2017-07-20
TN2012000028A1 (en) 2013-09-19
US9717739B2 (en) 2017-08-01
HRP20191049T1 (hr) 2019-09-20
WO2011009531A3 (fr) 2011-04-28
PE20121085A1 (es) 2012-08-04
UY32791A (es) 2011-02-28
ZA201201222B (en) 2022-11-30
JO3009B1 (ar) 2016-09-05

Similar Documents

Publication Publication Date Title
MA33445B1 (fr) Dérivés 17-hydroxy-17-pentafluoréthyl-estra-4,9(10)-diène-11-arylés, leur procédé de production et leur utilisation pour le traitement de maladies
MA33365B1 (fr) Dérivés de spiro[2.4]heptane pontés utiles en tant qu'agonistes du récepteur de alx et/ou du récepteur fprl2
WO2011009530A3 (fr) Dérivés 17-hydroxy-17-pentafluoroéthyl-estra-4,9(10)-diène-11-acyloxyalcénylphényle, procédés de préparation et utilisation pour le traitement de maladies
WO2011009529A3 (fr) Dérivés 17-hydroxy-17-pentafluoroéthyl-estra-4,9(10)-diène-11-méthylénoxyalcénylaryle, procédés de préparation et utilisation pour le traitement de maladies
MA30232B1 (fr) Inhibiteurs de kinase bases sur l'hydantoine
TN2010000230A1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
MA34099B1 (fr) Forme galénique parentérale libérant des inhibiteurs de l'aromatase et des gestagènes, pour le traitement de l'endométriose
Cao et al. Preliminary study of quercetin affecting the hypothalamic‐pituitary‐gonadal axis on rat endometriosis model
BRPI0506721A (pt) composto ou um sal de adição de ácido do mesmo
MA35867B1 (fr) Dérivés de la spiroindoline comme antagonistes du récepteur de l'hormone libérant la gonatrophine (gnrh)
WO2011009534A3 (fr) Dérivés 17-hydroxy-17-pentafluoroéthyl-estra-4,9(10)-diène-11-aryle, procédés de préparation et utilisation pour le traitement de maladies
MA34489B1 (fr) Agonistes du récepteur a1 à l'adénosine destinés au traitement du glaucome et de l'hypertension oculaire
MA38925A1 (fr) Dérivés de phénylalanine substitués
MA32997B1 (fr) Macrolide anti-inflammatoire
MA31902B1 (fr) Oxazolidinones pour le traitement et/ou la prophylaxie de l'insuffisance cardiaque
MA38465A1 (fr) Forme posologique de l'antagoniste du récepteur de la progestérone
MA38463A1 (fr) Dérivés de spiroindoline pour une utilisation en tant qu'antagonistes du récepteur de l'hormone de libération des gonadotrophines
UA59389U (ru) Способ лечения гиперпластических процессов матки
MA31523B1 (fr) Procédés et compositions pour traiter des maladies allergiques
BR112015001479A2 (pt) aperfeiçoamento de excitação sexual, desejo sexual, orgasmo e/ou prazer após administração de prasterona intravaginal (dhea) em mulheres que não sofrem ou independente de dispareunia ou outros sintomas de atrofia vulvo-vaginal
MA37836B1 (fr) Antagonistes du récepteur 5-ht3